Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | ST6GAL1 | P15907 | 2/20 | 0.54 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22894586 | 0.87 | VDR (0.67) | VDRCYP2C9HIF1AGPBAR1USP2 | |
| SCHEMBL20730002 | 0.86 | VDR (0.70) | VDRCYP2C9HIF1AGPBAR1USP2 | |
| SCHEMBL16299785 | 0.85 | EPHA2 (0.56) | VDRGPBAR1USP2EPHA2 | |
| SCHEMBL12994291 | 0.84 | VDR (0.61) | VDRCYP2C9HIF1AGPBAR1USP2 | |
| SCHEMBL10226269 | 0.84 | VDR (0.67) | VDRCYP2C9HIF1AGPBAR1USP2 | |
| SCHEMBL22871979 | 0.83 | VDR (0.82) | VDRCYP2C9HIF1AGPBAR1USP2 | |
| SCHEMBL17777260 | 0.83 | VDR (0.82) | VDRCYP2C9HIF1AGPBAR1USP2 | |
| SCHEMBL20980004 | 0.83 | VDR (0.82) | VDRCYP2C9HIF1AGPBAR1USP2 | |
| SCHEMBL7996253 | 0.83 | VDR (0.82) | VDRCYP2C9HIF1AGPBAR1USP2 | |
| SCHEMBL3694684 | 0.83 | VDR (0.82) | VDRCYP2C9HIF1AGPBAR1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150203847-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | ALNYLAM PHARMACEUTICALS INC (US) | 2015-07-23 | — | — | US | disclosed |
| US-8962580-B2 | Chemical modifications of monomers and oligonucleotides with cycloaddition | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20120035115-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203847-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | DNMT1, LCK, MCTS1 | VDR 1584/4885CYP2C9 2610/4885HIF1A 700/4885 |
| US-20120035115-A1 | CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION | DNMT1, LCK, MCTS1 | VDR 1584/4885CYP2C9 2610/4885HIF1A 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.